Minerva Neurosciences (NERV) Other financing activities (2014 - 2026)

Minerva Neurosciences (NERV) posted Other financing activities of $1.2 million for Q1 2026, down 98.0% on a QoQ basis from $60.0 million in Q1 2021.

Minerva Neurosciences (NERV) Other financing activities (2014 - 2026) Analysis & Trends

Minerva Neurosciences' Other financing activities history runs 9 years deep, the most recent figure standing at $1.2 million for Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $80.0 million, changed N/A from the prior year.
Other financing activities was $1.2 million for Q1 2026 at Minerva Neurosciences, down from $60.0 million in the prior quarter.
Across five years, Other financing activities topped out at $1.2 million in Q1 2026 and bottomed at $1.2 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Minerva Neurosciences	195.10 Mn	195.10 Mn	-

Download Data